PDCD1 and metastatic malignant neoplasm in the lymph nodes: Overall, the pooled ORR was 0.20, and the efficacy and safety profiles were similar to those reported in the meta-analysis performed by Zhang et al. Nonetheless, among the subgroup analyses stratified by the location of metastasis or primary tumor, PD-1/PD-L1 inhibitors produced encouraging ORR in advanced UC patients with lymph node-only metastasis compared to those with visceral metastasis (0.41 VS.